Health and Nutrition

Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women (R21)

The purpose of this funding opportunity announcement (FOA) is to (1) promote preclinical, translational, clinical and epidemiological research in pain medications use in children or in pregnant women to fill knowledge gaps in the safe use of the pain medications in these special populations; and (2) develop effective instruments or approaches to assess and evaluate maternal and child outcomes of pain medication treatment.

Ruth L. Kirschstein National Research Service Award (NRSA) Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

This Funding Opportunity Announcement (FOA) will support students at institutions without formal NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists.

Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01)

The mission of the NIH Countermeasures Against Chemical Threats (CounterACT) program is to develop new and improved therapeutics to treat and/or prevent injuries resulting from exposure to chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents and toxic industrial chemicals and materials.

Time-Sensitive Obesity Policy and Program Evaluation (R01)

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity.This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding.All applications to this FOA must demonstrate that the evaluation of an obesity related po

PHS 2016-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the Administration for Children and Families (ACF), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications.

Research on the Mechanisms and/or Behavioral Outcomes of Multisensory Processing (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that elucidate the mechanisms and/or behavioral outcomes of multisensory processing, the integration or processing of at least two distinct types of sensory input as defined by distinct receptor-type transduction, neural pathways and cognate perceptual quality. Specifically, multiple sensory inputs may include the major traditional modalities of hearing, vision, taste, smell, balance, and touch.

The Health of Sexual and Gender Minority (SGM) Populations (R03)

The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of diverse population groups and thereby improve the effectiveness of health interventions and services for individuals within those groups. Priority is placed on understudied populations distinctive health risk profiles. This funding opportunity announcement (FOA) focuses on sexual and gender minority (SGM) populations, including lesbian, gay, bisexual, transgender, and intersex populations.

PHS 2016-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])

This Funding Opportunity Announcement (FOA) issued by the National Institutes of Health (NIH) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2016-2 SBIR/STTR Program Descriptions and Research Topics for NIH.)

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44)

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing.

Advancing Understanding, Prevention, and Management of Infections Transmitted from Women to their Infants (R01)

The purpose of this funding opportunity announcement (FOA) is to stimulate investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from women to their offspring during pregnancy, labor and delivery, and breastfeeding. NICHD is committed to supporting research that will increase scientific understanding of and treatments for high-priority perinatal infections.